<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Ocular Hypertension - Elevated Eye Pressure Guide | Vision Health Portal</title>
    <meta name="description"
        content="Comprehensive guide to ocular hypertension: elevated intraocular pressure without optic nerve damage, glaucoma suspect, risk factors, monitoring with OCT and visual fields, preventive treatment considerations.">
    <link rel="stylesheet" href="../style.css">
    <link rel="stylesheet" href="disease-style.css">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.0.0/css/all.min.css">
</head>

<body>
    <header>
        <a href="../index.html" class="logo">
            <i class="fas fa-eye"></i> VisionHealth
        </a>
        <nav>
            <ul>
                <li><a href="../index.html">Home</a></li>
                <li><a href="../tests/index.html">Vision Tests</a></li>
                <li><a href="../innovations.html">Innovations</a></li>
            </ul>
        </nav>
    </header>

    <div class="disease-hero">
        <h1>Ocular Hypertension</h1>
        <p>Elevated Eye Pressure Without Glaucoma Damage</p>
        <span class="category"><i class="fas fa-tag"></i> Glaucoma Suspect</span>
    </div>

    <div class="disease-content-wrapper">
        <aside class="toc">
            <h3>Contents</h3>
            <ul>
                <li><a href="#overview">Overview</a></li>
                <li><a href="#definition">Definition & Diagnosis</a></li>
                <li><a href="#causes">Causes & Risk Factors</a></li>
                <li><a href="#symptoms">Symptoms</a></li>
                <li><a href="#evaluation">Evaluation & Testing</a></li>
                <li><a href="#risk">Risk Assessment</a></li>
                <li><a href="#treatment">Treatment Decisions</a></li>
                <li><a href="#monitoring">Monitoring</a></li>
                <li><a href="#prognosis">Prognosis</a></li>
                <li><a href="#when-to-see">When to See a Doctor</a></li>
            </ul>
        </aside>

        <main class="disease-content">
            <section id="overview">
                <h2>What Is Ocular Hypertension?</h2>
                <p>Ocular hypertension (OHT) is a condition in which intraocular pressure (IOP)—the fluid pressure
                    inside the eye—is consistently elevated above the normal range (typically >21 mmHg), but there is no
                    evidence of glaucomatous optic nerve damage or visual field loss. In other words, the pressure is
                    high, but the optic nerve remains healthy and vision is intact. People with ocular hypertension are
                    considered "glaucoma suspects" because elevated IOP is the primary risk factor for developing
                    primary open-angle glaucoma (POAG), though not everyone with high pressure will develop glaucoma.
                </p>

                <p>Ocular hypertension is common, affecting approximately 3-6% of the population over age 40, with
                    prevalence increasing with age. It is asymptomatic—detected only through routine eye pressure
                    screening during comprehensive eye exams. The key clinical challenge is determining which patients
                    with ocular hypertension are at high risk of progressing to glaucoma and require preventive
                    treatment (IOP-lowering medications) versus those who can be safely monitored without treatment.
                    Large clinical trials have helped identify risk factors and guide treatment decisions.</p>

                <div class="key-facts">
                    <h3><i class="fas fa-info-circle"></i> Key Facts About Ocular Hypertension</h3>
                    <ul>
                        <li><strong>Elevated IOP without damage:</strong> Pressure >21 mmHg but optic nerve and visual
                            fields normal.</li>
                        <li><strong>Asymptomatic:</strong> No symptoms; detected during routine eye exams.</li>
                        <li><strong>Glaucoma suspect:</strong> At risk for developing glaucoma, but not everyone does.
                        </li>
                        <li><strong>Risk of progression:</strong> ~10% develop glaucoma over 5 years if untreated
                            (varies by risk factors).</li>
                        <li><strong>Treatment reduces risk:</strong> IOP-lowering drops reduce glaucoma conversion by
                            ~50%.</li>
                        <li><strong>Regular monitoring essential:</strong> Optic nerve exams, OCT, visual fields to
                            detect early damage.</li>
                        <li><strong>Not all need treatment:</strong> Low-risk patients can be observed; high-risk may
                            benefit from preventive drops.</li>
                        <li><strong>Different from normal-tension glaucoma:</strong> OHT has high pressure without
                            damage; NTG has damage despite normal pressure.</li>
                    </ul>
                </div>

                <p>Understanding ocular hypertension helps patients and doctors make informed decisions about monitoring
                    and treatment to prevent vision loss from glaucoma.</p>
            </section>

            <section id="definition">
                <h2>Definition and Diagnosis</h2>

                <h3>Diagnostic Criteria for Ocular Hypertension</h3>
                <ul>
                    <li><strong>Intraocular pressure >21 mmHg</strong> (measured on multiple occasions)
                        <ul>
                            <li>Normal IOP range: 10-21 mmHg</li>
                            <li>Statistical definition: OHT is IOP >2 standard deviations above mean (~21 mmHg)</li>
                            <li>Pressure should be consistently elevated (not single measurement)</li>
                        </ul>
                    </li>
                    <li><strong>Normal optic nerve appearance</strong>
                        <ul>
                            <li>No glaucomatous cupping, rim thinning, or hemorrhages</li>
                            <li>Healthy cup-to-disc ratio (typically <0.5-0.6, symmetric between eyes)</li>
                        </ul>
                    </li>
                    <li><strong>Normal visual fields</strong>
                        <ul>
                            <li>Automated perimetry shows no glaucomatous defects</li>
                        </ul>
                    </li>
                    <li><strong>Open drainage angles on gonioscopy</strong>
                        <ul>
                            <li>Angles where aqueous drains are open (not narrow or closed)</li>
                            <li>Distinguishes from angle-closure mechanisms</li>
                        </ul>
                    </li>
                    <li><strong>No other secondary cause of elevated IOP</strong>
                        <ul>
                            <li>Not from uveitis, steroid use, trauma, etc.</li>
                        </ul>
                    </li>
                </ul>

                <h3>Important Distinction: OHT vs. Glaucoma</h3>
                <ul>
                    <li><strong>Ocular Hypertension:</strong> High IOP but NO optic nerve damage or vision loss</li>
                    <li><strong>Glaucoma:</strong> Optic nerve damage (with or without elevated IOP) causing progressive
                        visual field loss</li>
                    <li>OHT is a risk factor for glaucoma, not glaucoma itself</li>
                </ul>
            </section>

            <section id="causes">
                <h2>Causes and Risk Factors</h2>

                <h3>Mechanism of Elevated IOP</h3>
                <ul>
                    <li>Increased resistance to aqueous humor outflow through trabecular meshwork</li>
                    <li>Drainage system less efficient, but not completely blocked (as in glaucoma)</li>
                    <li>Exact reason unclear; likely genetic, anatomical factors</li>
                </ul>

                <h3>Risk Factors for Ocular Hypertension</h3>

                <h4>Age</h4>
                <ul>
                    <li>Prevalence increases with age</li>
                    <li>More common >40 years</li>
                </ul>

                <h4>Race</h4>
                <ul>
                    <li><strong>African descent:</strong> Higher prevalence of OHT and higher risk of progression to
                        glaucoma</li>
                    <li>Hispanic individuals also at increased risk</li>
                </ul>

                <h4>Family History of Glaucoma</h4>
                <ul>
                    <li>Genetic component</li>
                    <li>First-degree relatives of glaucoma patients at higher risk</li>
                </ul>

                <h4>Thinner Central Corneal Thickness (CCT)</h4>
                <ul>
                    <li><strong>Very important risk factor</strong></li>
                    <li>Thin corneas (<555 μm) associated with higher true IOP and higher glaucoma risk</li>
                    <li>Tonometry measures pressure through cornea; thin corneas may underestimate true IOP</li>
                    <li>Thick corneas (>600 μm) may overestimate IOP (lower glaucoma risk)</li>
                </ul>

                <h4>Larger Cup-to-Disc Ratio (Even if "Normal")</h4>
                <ul>
                    <li>Higher baseline cupping increases risk of progression</li>
                </ul>

                <h4>Myopia (Nearsightedness)</h4>
                <ul>
                    <li>Associated with higher glaucoma risk</li>
                </ul>

                <h4>Diabetes</h4>
                <ul>
                    <li>Possible increased risk</li>
                </ul>

                <h4>Cardiovascular Disease</h4>
                <ul>
                    <li>Vascular factors may play role</li>
                </ul>

                <h3>Secondary Causes of Elevated IOP (Excluded from OHT Definition)</h3>
                <ul>
                    <li>Steroid-induced (topical, inhaled, systemic steroids)</li>
                    <li>Uveitis (intraocular inflammation)</li>
                    <li>Trauma</li>
                    <li>Pseudoexfoliation syndrome</li>
                    <li>Pigment dispersion syndrome</li>
                    <li>These are forms of secondary glaucoma, not primary OHT</li>
                </ul>
            </section>

            <section id="symptoms">
                <h2>Symptoms</h2>

                <h3>Asymptomatic Condition</h3>
                <ul>
                    <li><strong>No symptoms</strong> in ocular hypertension</li>
                    <li>Elevated IOP alone does not cause:
                        <ul>
                            <li>Pain (unless pressure extremely high, as in acute angle-closure)</li>
                            <li>Redness</li>
                            <li>Blurred vision</li>
                            <li>Visual field defects (by definition, fields are normal in OHT)</li>
                        </ul>
                    </li>
                    <li>Detected only by tonometry during eye exam</li>
                </ul>

                <h3>Importance of Screening</h3>
                <ul>
                    <li>Regular comprehensive eye exams critical for detection</li>
                    <li>Recommended frequency:
                        <ul>
                            <li>Age 40-54: Every 2-4 years</li>
                            <li>Age 55-64: Every 1-3 years</li>
                            <li>Age 65+: Every 1-2 years</li>
                            <li>Higher risk (African descent, family history): More frequent</li>
                        </ul>
                    </li>
                </ul>
            </section>

            <section id="evaluation">
                <h2>Evaluation and Testing</h2>

                <h3>Comprehensive Eye Examination</h3>

                <h4>Tonometry (IOP Measurement)</h4>
                <ul>
                    <li><strong>Goldmann applanation tonometry:</strong> Gold standard</li>
                    <li>Measure on multiple visits to confirm elevation</li>
                    <li>Diurnal variation: IOP fluctuates throughout day; may measure at different times</li>
                </ul>

                <h4>Central Corneal Thickness (Pachymetry)</h4>
                <ul>
                    <li>Measure corneal thickness with ultrasound pachymeter</li>
                    <li>Adjusts interpretation of IOP readings</li>
                    <li>Essential for risk stratification</li>
                </ul>

                <h4>Gonioscopy</h4>
                <ul>
                    <li>Examine drainage angle with special lens</li>
                    <li>Confirm angle is open (not narrow/closed)</li>
                </ul>

                <h4>Optic Nerve Examination</h4>
                <ul>
                    <li>Dilated fundus exam</li>
                    <li>Assess cup-to-disc ratio, rim thickness, hemorrhages</li>
                    <li>Document baseline appearance</li>
                    <li>Serial exams to detect changes over time</li>
                </ul>

                <h4>Optical Coherence Tomography (OCT) of Optic Nerve and Retinal Nerve Fiber Layer (RNFL)</h4>
                <ul>
                    <li>High-resolution imaging of optic nerve structure</li>
                    <li>Measures RNFL thickness (early glaucoma causes thinning)</li>
                    <li>Baseline OCT critical for detecting subtle progression</li>
                    <li>Repeat periodically to monitor</li>
                </ul>

                <h4>Visual Field Testing (Perimetry)</h4>
                <ul>
                    <li>Automated perimetry (Humphrey, Octopus)</li>
                    <li>Baseline fields to confirm normal</li>
                    <li>Repeat annually or biannually to detect early defects</li>
                </ul>
            </section>

            <section id="risk">
                <h2>Risk Assessment for Progression to Glaucoma</h2>

                <h3>Ocular Hypertension Treatment Study (OHTS)</h3>
                <ul>
                    <li>Landmark trial: untreated OHT patients developed glaucoma at ~10% over 5 years (~2% per year)
                    </li>
                    <li>Treatment with IOP-lowering drops reduced risk by ~50% (to ~5% over 5 years)</li>
                    <li>Identified high-risk and low-risk features</li>
                </ul>

                <h3>High-Risk Features (Higher Likelihood of Progression)</h3>
                <ul>
                    <li><strong>Older age</strong></li>
                    <li><strong>Higher baseline IOP</strong> (e.g., >30 mmHg much higher risk than 22-24 mmHg)</li>
                    <li><strong>Thinner central corneal thickness</strong> (<555 μm)</li>
                    <li><strong>Larger cup-to-disc ratio</strong> (even if "normal")</li>
                    <li><strong>Vertical cup-to-disc ratio >0.5</strong></li>
                    <li><strong>Pattern standard deviation (PSD) on visual fields</strong> (borderline abnormal)</li>
                    <li><strong>African descent</strong></li>
                    <li><strong>Family history of glaucoma</strong></li>
                </ul>

                <h3>Low-Risk Features</h3>
                <ul>
                    <li>Younger age</li>
                    <li>IOP only mildly elevated (22-24 mmHg)</li>
                    <li>Thick corneas (>600 μm)</li>
                    <li>Small cup-to-disc ratio (<0.3)< /li>
                </ul>

                <h3>Risk Calculators</h3>
                <ul>
                    <li>Online tools based on OHTS data estimate 5-year glaucoma risk</li>
                    <li>Help guide treatment decisions</li>
                </ul>
            </section>

            <section id="treatment">
                <h2>Treatment Decisions</h2>

                <h3>Observation vs. Treatment</h3>
                <p>Not all patients with ocular hypertension require treatment. Decision based on risk assessment:</p>

                <h3>Observation (No Treatment) - Low-Risk Patients</h3>
                <ul>
                    <li><strong>Indications:</strong>
                        <ul>
                            <li>Low 5-year glaucoma risk (<5-10%)< /li>
                            <li>IOP 22-24 mmHg</li>
                            <li>Thick corneas, small cups</li>
                            <li>Young age, no family history</li>
                        </ul>
                    </li>
                    <li><strong>Management:</strong>
                        <ul>
                            <li>Close monitoring (see below)</li>
                            <li>Regular exams, OCT, visual fields</li>
                            <li>Initiate treatment if progression detected</li>
                        </ul>
                    </li>
                </ul>

                <h3>Preventive Treatment (IOP-Lowering Medications) - High-Risk Patients</h3>
                <ul>
                    <li><strong>Indications:</strong>
                        <ul>
                            <li>High 5-year glaucoma risk (>10-15%)</li>
                            <li>Multiple high-risk features (thin cornea, high IOP, large cups, African descent, family
                                history)</li>
                            <li>Very high IOP (>28-30 mmHg)</li>
                            <li>Borderline optic nerve or visual field changes</li>
                        </ul>
                    </li>
                    <li><strong>Goal:</strong> Lower IOP by ~20-30% to reduce glaucoma risk</li>
                    <li><strong>Medications:</strong> Same as for glaucoma
                        <ul>
                            <li><strong>Prostaglandin analogs:</strong> Latanoprost, travoprost, bimatoprost
                                (first-line; most effective, once-daily)</li>
                            <li><strong>Beta-blockers:</strong> Timolol (twice daily)</li>
                            <li><strong>Alpha-agonists:</strong> Brimonidine</li>
                            <li><strong>Carbonic anhydrase inhibitors:</strong> Dorzolamide, brinzolamide</li>
                            <li>Combination drops if needed</li>
                        </ul>
                    </li>
                    <li><strong>Evidence:</strong> OHTS showed treatment reduced progression by ~50%</li>
                </ul>

                <h3>Shared Decision-Making</h3>
                <ul>
                    <li>Discuss risks/benefits with patient</li>
                    <li>Consider patient preferences, life expectancy, cost of medications, side effects</li>
                    <li>Some lower-risk patients may choose treatment for peace of mind</li>
                    <li>Some higher-risk patients may prefer observation if closely monitored</li>
                </ul>
            </section>

            <section id="monitoring">
                <h2>Monitoring Strategy</h2>

                <h3>For Untreated (Observation) Patients</h3>
                <ul>
                    <li><strong>IOP checks:</strong> Every 4-6 months</li>
                    <li><strong>Optic nerve exam:</strong> Every 6-12 months</li>
                    <li><strong>OCT (RNFL/optic nerve):</strong> Annually</li>
                    <li><strong>Visual field testing:</strong> Annually or biannually</li>
                    <li>More frequent if borderline findings or risk factors</li>
                </ul>

                <h3>For Treated Patients</h3>
                <ul>
                    <li>Same monitoring as above to ensure no progression despite treatment</li>
                    <li>Check IOP response to medication (~4-6 weeks after starting)</li>
                    <li>Ongoing monitoring: Every 4-6 months</li>
                </ul>

                <h3>When to Initiate Treatment (If Observing)</h3>
                <ul>
                    <li>Development of optic nerve changes (cupping progression, RNFL thinning on OCT)</li>
                    <li>Visual field defects</li>
                    <li>IOP rising significantly</li>
                </ul>

                <h3>When to Intensify Treatment (If Already Treated)</h3>
                <ul>
                    <li>Despite treatment, optic nerve or visual field changes detected</li>
                    <li>Add second medication or switch to more effective agent</li>
                </ul>
            </section>

            <section id="prognosis">
                <h2>Prognosis and Outcomes</h2>

                <h3>Natural History (Untreated)</h3>
                <ul>
                    <li>~10% develop glaucoma over 5 years (OHTS data)</li>
                    <li>Risk varies widely based on individual risk factors</li>
                    <li>Some patients remain stable with OHT for decades without developing glaucoma</li>
                    <li>Others progress despite normal-appearing risk profile</li>
                </ul>

                <h3>With Treatment</h3>
                <ul>
                    <li>IOP lowering reduces risk by ~50%</li>
                    <li>~5% develop glaucoma over 5 years with treatment</li>
                    <li>If glaucoma detected early and treated, excellent prognosis for preserving vision</li>
                </ul>

                <h3>Lifelong Condition</h3>
                <ul>
                    <li>OHT is chronic</li>
                    <li>Requires ongoing monitoring throughout life</li>
                    <li>IOP typically does not "normalize" spontaneously</li>
                </ul>

                <h3>Excellent Vision Prognosis If Monitored Properly</h3>
                <ul>
                    <li>With appropriate monitoring and treatment (if needed), vast majority maintain excellent vision
                    </li>
                    <li>Key: Regular follow-up to detect glaucoma at earliest stage</li>
                </ul>
            </section>

            <section id="when-to-see">
                <h2>When to See a Doctor</h2>

                <h3>Regular Eye Exams Critical</h3>
                <ul>
                    <li>Since OHT is asymptomatic, only detected by screening</li>
                    <li>Adults >40: Comprehensive eye exam every 1-4 years depending on risk factors</li>
                    <li>High-risk individuals: More frequent exams</li>
                </ul>

                <h3>If Diagnosed with Ocular Hypertension</h3>
                <ul>
                    <li>Follow recommended monitoring schedule</li>
                    <li>Don't miss appointments—critical for detecting early glaucoma</li>
                    <li>If on treatment, take drops consistently as prescribed</li>
                </ul>

                <h3>Questions to Ask Your Doctor</h3>
                <ul>
                    <li>What is my IOP level?</li>
                    <li>What is my central corneal thickness?</li>
                    <li>What is my estimated risk of developing glaucoma?</li>
                    <li>Do I need treatment now, or can I be monitored?</li>
                    <li>How often should I have follow-up exams and tests?</li>
                    <li>What are the risks and benefits of starting IOP-lowering drops?</li>
                    <li>What should I watch for?</li>
                </ul>
            </section>

            <div class="alert-box info">
                <h4><i class="fas fa-lightbulb"></i> Bottom Line</h4>
                <p>Ocular hypertension is elevated intraocular pressure (IOP >21 mmHg) without optic nerve damage or
                    visual field loss. It's asymptomatic and detected only during routine eye exams with tonometry.
                    While OHT is a risk factor for glaucoma, not everyone with high pressure develops glaucoma—risk
                    depends on factors like age, corneal thickness, optic nerve appearance, race, and family history.
                    Large studies show that about 10% of untreated OHT patients develop glaucoma over 5 years, but
                    preventive IOP-lowering drops reduce this risk by 50%. Treatment decisions are individualized:
                    low-risk patients can be safely monitored with regular exams, OCT, and visual fields, while
                    high-risk patients may benefit from preventive medication. Lifelong monitoring is essential to
                    detect early glaucoma and preserve vision. If you're diagnosed with ocular hypertension, work
                    closely with your ophthalmologist to determine the best strategy—observation or treatment—and commit
                    to regular follow-up to protect your sight.</p>
            </div>

            <div class="related-diseases">
                <h3>Related Eye Conditions</h3>
                <div class="related-links">
                    <a href="glaucoma.html">Open-Angle Glaucoma</a>
                    <a href="angle-closure-glaucoma.html">Angle-Closure Glaucoma</a>
                    <a href="cataracts.html">Cataracts</a>
                </div>
            </div>
        </main>
    </div>

    <footer>
        <div class="footer-content">
            <p>&copy; 2025 Vision Health Portal. All rights reserved.</p>
            <p class="designer-credit">Designed by RITIK DHAGE</p>
            <p style="font-size: 0.85rem; margin-top: 1rem; opacity: 0.8;">
                <i class="fas fa-info-circle"></i> This information is for educational purposes only and is not a
                substitute for professional medical advice, diagnosis, or treatment.
            </p>
        </div>
    </footer>
</body>

</html>